Simmons et al. 10.1073/pnas.0505577102.

Supporting Information

Files in this Data Supplement:

Supporting Table 1
Supporting Figure 5




Supporting Figure 5

Fig. 5. ACE2-mediated infection of SARS-CoV spike (S) protein-expressing cells. Pseudovirions incorporating ACE2 [termed HIV-luc(ACE2)], amphotropic MLV envelope, SARS-CoV S protein, or no surface glycoprotein [termed HIV-luc(bald)] were used to infect 293T cells transfected with empty vector pCDNA3.1 ACE2 or pCAGGS SARS-CoV S. Results are presented on a log10 scale of relative light units and represent the mean of samples run in triplicate (±SD).





Table 1. Inhibition of SARS-CoV S-mediated entry by cathepsin L inhibitors

Inhibitor*

IC95 (mM)**

HIV-luc(SARS-S) HIV-luc(VSV-G)

Z-FF-FMK

0.8

>10

Z-FY-CHO

1.8

>10

Z-FY(tBu)-DMK

0.8

>10

1-Naphthalenesulfonyl-IW-CHO

1.3

>10

MDL28170

2.0

>10

CA-074

>200

>200

SARS, severe acute respiratory syndrome; SARS-CoV, SARS-associated coronavirus; S, spike; VSV, vesicular stomatitis virus; FMK, fluoromethyl ketone; DMK, dimethyl ketone.

*Obtained from Calbiochem (San Diego)

**Calculated from infection on 293T-ACE2-transfected cells.